{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,23]],"date-time":"2026-07-23T01:41:24Z","timestamp":1784770884931,"version":"3.55.0"},"reference-count":122,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,5,2]],"date-time":"2025-05-02T00:00:00Z","timestamp":1746144000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","surveyophthalmol.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Survey of Ophthalmology"],"published-print":{"date-parts":[[2025,11]]},"DOI":"10.1016\/j.survophthal.2025.04.004","type":"journal-article","created":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T02:12:27Z","timestamp":1746065547000},"page":"1090-1110","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"title":["Anatomic biomarkers as potential endpoints in diabetic macular edema: A systematic literature review with identification of macular volume as a key surrogate for visual acuity"],"prefix":"10.1016","volume":"70","author":[{"given":"Aude","family":"Couturier","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charles C.","family":"Wykoff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"Lupidi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patricia","family":"Udaondo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tunde","family":"Peto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pierre-Jean","family":"Pintard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"4","key":"10.1016\/j.survophthal.2025.04.004_bib1","first-page":"785","article-title":"Burden of disease and costs associated with type 2 diabetes in emerging and established markets: systematic review analyses","volume":"21","author":"Alzaid","year":"2021","journal-title":"Expert Rev Pharm Outcomes Res"},{"issue":"5","key":"10.1016\/j.survophthal.2025.04.004_bib2","doi-asserted-by":"crossref","first-page":"e257","DOI":"10.1016\/S2589-7500(23)00022-5","article-title":"A deep learning model for novel systemic biomarkers in photographs of the external eye: a retrospective study","volume":"5","author":"Babenko","year":"2023","journal-title":"Lancet Digit Health"},{"issue":"2","key":"10.1016\/j.survophthal.2025.04.004_bib3","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1007\/s10633-017-9601-2","article-title":"Multifocal electroretinography changes at the 1-year follow-up in a cohort of diabetic macular edema patients treated with ranibizumab","volume":"135","author":"Baget-Bernaldiz","year":"2017","journal-title":"Doc Ophthalmol"},{"issue":"5","key":"10.1016\/j.survophthal.2025.04.004_bib4","doi-asserted-by":"crossref","first-page":"1012","DOI":"10.1038\/s41433-021-01542-w","article-title":"Extended real-world experience with the ILUVIEN (fluocinolone acetonide) implant in the United Kingdom: 3-year results from the Medisoft audit study","volume":"36","author":"Bailey","year":"2022","journal-title":"Eye"},{"issue":"19","key":"10.1016\/j.survophthal.2025.04.004_bib5","doi-asserted-by":"crossref","first-page":"1880","DOI":"10.1001\/jama.2019.5790","article-title":"Effect of initial management with aflibercept vs laser photocoagulation vs observation on vision loss among patients with diabetic macular edema involving the center of the macula and good visual acuity: a randomized clinical trial","volume":"321","author":"Baker","year":"2019","journal-title":"JAMA"},{"issue":"33","key":"10.1016\/j.survophthal.2025.04.004_bib6","doi-asserted-by":"crossref","first-page":"3968","DOI":"10.1200\/JCO.2015.63.3651","article-title":"Biomarker: predictive or prognostic?","volume":"33","author":"Ballman","year":"2015","journal-title":"J Clin Oncol"},{"issue":"3","key":"10.1016\/j.survophthal.2025.04.004_bib7","doi-asserted-by":"crossref","first-page":"494","DOI":"10.11124\/JBIES-22-00430","article-title":"The revised JBI critical appraisal tool for the assessment of risk of bias for randomized controlled trials","volume":"21","author":"Barker","year":"2023","journal-title":"JBI Evid Synth"},{"issue":"9","key":"10.1016\/j.survophthal.2025.04.004_bib8","first-page":"2606","article-title":"Long-term outcomes of macular laser photocoagulation in the treatment of clinically significant diabetic macular edema (CSDME)-real world experience","volume":"60","author":"Best","year":"2019","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"10","key":"10.1016\/j.survophthal.2025.04.004_bib9","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1089\/jop.2018.0112","article-title":"Factors predicting treatment response in anti-vascular endothelial growth factor naive diabetic macular edema patients treated with intravitreal bevacizumab","volume":"35","author":"Bezzina","year":"2019","journal-title":"J Ocul Pharm Ther"},{"issue":"6","key":"10.1016\/j.survophthal.2025.04.004_bib10","doi-asserted-by":"crossref","first-page":"1030.e1","DOI":"10.1016\/j.ajo.2009.01.009","article-title":"Intravitreal bevacizumab for diabetic macular edema associated with severe capillary loss: one-year results of a pilot study","volume":"147","author":"Bonini-Filho","year":"2009","journal-title":"Am J Ophthalmol"},{"issue":"2","key":"10.1016\/j.survophthal.2025.04.004_bib11","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1097\/IAE.0000000000002852","article-title":"Association of serum vasogenic and proinflammatory factors with clinical response to anti-vascular endothelial growth factor for diabetic macular edema","volume":"41","author":"Brito","year":"2021","journal-title":"Retina"},{"issue":"10","key":"10.1016\/j.survophthal.2025.04.004_bib12","doi-asserted-by":"crossref","first-page":"2044","DOI":"10.1016\/j.ophtha.2015.06.017","article-title":"Intravitreal aflibercept for diabetic macular edema: 100-week results from the VISTA and VIVID studies","volume":"122","author":"Brown","year":"2015","journal-title":"Ophthalmology"},{"issue":"12","key":"10.1016\/j.survophthal.2025.04.004_bib13","doi-asserted-by":"crossref","first-page":"1736","DOI":"10.4103\/ijo.IJO_1240_18","article-title":"Diabetic macular edema: evidence-based management","volume":"66","author":"Browning","year":"2018","journal-title":"Indian J Ophthalmol"},{"issue":"12","key":"10.1016\/j.survophthal.2025.04.004_bib14","doi-asserted-by":"crossref","first-page":"1036","DOI":"10.3109\/02713680903288937","article-title":"Macular thickness measured by optical coherence tomography in a healthy population before and after uncomplicated cataract phacoemulsification surgery","volume":"34","author":"Cagini","year":"2009","journal-title":"Curr Eye Res"},{"key":"10.1016\/j.survophthal.2025.04.004_bib15","unstructured":"Canadian Agency for Drugs and Technologies in Health. CADTH Methods and Guidelines. PRESS - Peer Review of Electronic Search Strategies: 2015 Guideline Explanation and Elaboration (PRESS E&E); 2016. Available at: \u3008https:\/\/www.cadth.ca\/sites\/default\/files\/pdf\/CP0015_PRESS_Update_Report_2016.pdf\u3009 [Accessed March 2024]."},{"issue":"12","key":"10.1016\/j.survophthal.2025.04.004_bib16","doi-asserted-by":"crossref","first-page":"1950","DOI":"10.3390\/cells11121950","article-title":"Current and novel therapeutic approaches for treatment of diabetic macular edema","volume":"11","author":"Chauhan","year":"2022","journal-title":"Cells"},{"issue":"7","key":"10.1016\/j.survophthal.2025.04.004_bib17","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1038\/nrd.2016.81","article-title":"Use of surrogate end points in healthcare policy: a proposal for adoption of a validation framework","volume":"15","author":"Ciani","year":"2016","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.survophthal.2025.04.004_bib18","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2023.102283","article-title":"A framework for the definition and interpretation of the use of surrogate endpoints in interventional trials","volume":"65","author":"Ciani","year":"2023","journal-title":"EClinicalMedicine"},{"issue":"13","key":"10.1016\/j.survophthal.2025.04.004_bib19","doi-asserted-by":"crossref","first-page":"1437","DOI":"10.1001\/jama.2009.1409","article-title":"Using effectiveness and cost-effectiveness to make drug coverage decisions: a comparison of Britain, Australia, and Canada","volume":"302","author":"Clement","year":"2009","journal-title":"JAMA"},{"issue":"6","key":"10.1016\/j.survophthal.2025.04.004_bib20","first-page":"981","article-title":"Short-term outcomes after the loading phase of intravitreal bevacizumab and subthreshold macular laser in non-center involved diabetic macular edema","volume":"11","author":"Cuervo-Lozano","year":"2018","journal-title":"Int J Ophthalmol"},{"issue":"1","key":"10.1016\/j.survophthal.2025.04.004_bib21","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1007\/s40123-019-00224-x","article-title":"Clinical outcomes of a treat and extend regimen with intravitreal aflibercept injections in patients with diabetic macular edema: experience in clinical practice","volume":"9","author":"Curry","year":"2020","journal-title":"Ophthalmol Ther"},{"key":"10.1016\/j.survophthal.2025.04.004_bib22","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1007\/s10072-020-04802-x","article-title":"Two-year macular volume assessment in multiple sclerosis patients treated with fingolimod","volume":"42","author":"d\u2019Ambrosio","year":"2021","journal-title":"Neurol Sci"},{"issue":"2","key":"10.1016\/j.survophthal.2025.04.004_bib23","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1001\/jama.2019.20288","article-title":"FDA approval and regulation of pharmaceuticals, 1983\u20132018","volume":"323","author":"Darrow","year":"2020","journal-title":"JAMA"},{"key":"10.1016\/j.survophthal.2025.04.004_bib24","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/j.preteyeres.2017.10.006","article-title":"Mechanisms of macular edema: beyond the surface","volume":"63","author":"Daruich","year":"2018","journal-title":"Prog Retin Eye Res"},{"issue":"12","key":"10.1016\/j.survophthal.2025.04.004_bib25","doi-asserted-by":"crossref","first-page":"722","DOI":"10.3928\/23258160-20240621-04","article-title":"Central retinal thickness variability as a predictive factor for visual acuity after dexamethasone implant in retinal vein occlusion","volume":"55","author":"Daugirdas","year":"2024","journal-title":"Ophthalmic Surg Lasers Imaging Retin"},{"issue":"5","key":"10.1016\/j.survophthal.2025.04.004_bib26","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1016\/S0197-2456(01)00153-2","article-title":"Considerations in the evaluation of surrogate endpoints in clinical trials: summary of a National Institutes of Health workshop","volume":"22","author":"De Gruttola","year":"2001","journal-title":"Control Clin Trials"},{"issue":"5","key":"10.1016\/j.survophthal.2025.04.004_bib27","doi-asserted-by":"crossref","first-page":"e249","DOI":"10.1016\/S2589-7500(23)00047-X","article-title":"AI for identification of systemic biomarkers from external eye photos: a promising field in the oculomics revolution","volume":"5","author":"DeBuc","year":"2023","journal-title":"Lancet Digit Health"},{"issue":"1","key":"10.1016\/j.survophthal.2025.04.004_bib28","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1007\/s10792-007-9097-y","article-title":"A randomized, placebo-controlled clinical trial of intravitreal triamcinolone for refractory diabetic macular edema","volume":"28","author":"Dehghan","year":"2008","journal-title":"Int Ophthalmol"},{"issue":"9","key":"10.1016\/j.survophthal.2025.04.004_bib29","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0257707","article-title":"Correction: aflibercept for treatment-na\u00efve diabetic macula oedema in a multi-ethnic population: real-world outcomes from North West London","volume":"16","author":"Dinah","year":"2021","journal-title":"PLoS One"},{"issue":"4","key":"10.1016\/j.survophthal.2025.04.004_bib30","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1001\/jama.2013.282034","article-title":"Clinical trial evidence supporting FDA approval of novel therapeutic agents, 2005\u20132012","volume":"311","author":"Downing","year":"2014","journal-title":"JAMA"},{"issue":"11","key":"10.1016\/j.survophthal.2025.04.004_bib31","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1038\/nrd4734","article-title":"Regulatory watch: characterizing the US FDA's approach to promoting transformative innovation","volume":"14","author":"Downing","year":"2015","journal-title":"Nat Rev Drug Discov"},{"issue":"12","key":"10.1016\/j.survophthal.2025.04.004_bib32","doi-asserted-by":"crossref","first-page":"1056","DOI":"10.1016\/j.oret.2019.06.010","article-title":"Higher-order assessment of OCT in diabetic macular edema from the VISTA study: ellipsoid zone dynamics and the retinal fluid index","volume":"3","author":"Ehlers","year":"2019","journal-title":"Ophthalmol Retin"},{"issue":"11","key":"10.1016\/j.survophthal.2025.04.004_bib33","doi-asserted-by":"crossref","first-page":"2312","DOI":"10.1016\/j.ophtha.2012.08.022","article-title":"Intravitreal ranibizumab for diabetic macular edema with prompt versus deferred laser treatment: three-year randomized trial results","volume":"119","author":"Elman","year":"2012","journal-title":"Ophthalmology"},{"issue":"6","key":"10.1016\/j.survophthal.2025.04.004_bib34","doi-asserted-by":"crossref","first-page":"746","DOI":"10.1177\/112067210501500614","article-title":"Posterior sub-tenon triamcinolone for refractory diabetic macular edema: a randomized clinical trial","volume":"15","author":"Entezari","year":"2005","journal-title":"Eur J Ophthalmol"},{"issue":"3-4","key":"10.1016\/j.survophthal.2025.04.004_bib35","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1159\/000371770","article-title":"Dexamethasone implants in patients with naive or refractory diffuse diabetic macular edema","volume":"233","author":"Escobar-Barranco","year":"2015","journal-title":"Ophthalmologica"},{"issue":"3","key":"10.1016\/j.survophthal.2025.04.004_bib36","first-page":"67","article-title":"Comparison of intravitreal bevacizumab and intravitreal diclofenac in the treatment of diabetic macular edema: a 6-month follow-up","volume":"6","author":"Faghihi","year":"2017","journal-title":"Med Hypothesis Discov Innov Ophthalmol"},{"issue":"4","key":"10.1016\/j.survophthal.2025.04.004_bib37","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1016\/j.joco.2016.08.007","article-title":"Comparison of subthreshold diode laser micropulse therapy versus conventional photocoagulation laser therapy as primary treatment of diabetic macular edema","volume":"28","author":"Fazel","year":"2016","journal-title":"J Curr Ophthalmol"},{"key":"10.1016\/j.survophthal.2025.04.004_bib38","doi-asserted-by":"crossref","DOI":"10.1155\/2020\/6794391","article-title":"Combination of intravitreal bevacizumab and topical dorzolamide versus intravitreal bevacizumab alone for diabetic macular edema: a randomized contralateral clinical trial","volume":"2020","author":"Fazel","year":"2020","journal-title":"Biomed Res Int"},{"issue":"2","key":"10.1016\/j.survophthal.2025.04.004_bib39","doi-asserted-by":"crossref","first-page":"164","DOI":"10.4103\/JOCO.JOCO_101_20","article-title":"Intravitreal injections of bevacizumab plus methotrexate versus bevacizumab alone for the treatment of diabetic macular edema: a randomized, sham-controlled trial","volume":"32","author":"Fazel","year":"2020","journal-title":"J Curr Ophthalmol"},{"issue":"6","key":"10.1016\/j.survophthal.2025.04.004_bib40","doi-asserted-by":"crossref","first-page":"536","DOI":"10.3928\/23258160-20160601-05","article-title":"Comparison of ranibizumab 0.5 mg versus 1.0 mg for the treatment of patients with clinically significant diabetic macular edema: a randomized, clinical trial","volume":"47","author":"Ferrone","year":"2016","journal-title":"Ophthalmic Surg Lasers Imaging Retin"},{"issue":"2","key":"10.1016\/j.survophthal.2025.04.004_bib41","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1016\/j.oret.2019.09.001","article-title":"Longitudinal panretinal leakage and ischemic indices in retinal vascular disease after aflibercept therapy: the PERMEATE study","volume":"4","author":"Figueiredo","year":"2020","journal-title":"Ophthalmol Retin"},{"issue":"5","key":"10.1016\/j.survophthal.2025.04.004_bib42","doi-asserted-by":"crossref","first-page":"1336","DOI":"10.1167\/iovs.18-26215","article-title":"Anatomic response to intravitreal dexamethasone implant and baseline aqueous humor cytokine levels in diabetic macular edema","volume":"60","author":"Figueras-Roca","year":"2019","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"10.1016\/j.survophthal.2025.04.004_bib43","doi-asserted-by":"crossref","DOI":"10.1155\/2020\/2561251","article-title":"Effectiveness of intravitreal ranibizumab in nonvitrectomized and vitrectomized eyes with diabetic macular edema: a two-year retrospective analysis","volume":"2020","author":"Gedar Totuk","year":"2020","journal-title":"J Ophthalmol"},{"issue":"4","key":"10.1016\/j.survophthal.2025.04.004_bib44","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1007\/s10792-016-0335-z","article-title":"Intravitreal diclofenac plus bevacizumab versus bevacizumab alone in treatment-naive diabetic macular edema: a randomized double-blind clinical trial","volume":"37","author":"Ghanbari","year":"2017","journal-title":"Int Ophthalmol"},{"issue":"6","key":"10.1016\/j.survophthal.2025.04.004_bib45","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1097\/00006982-200212000-00012","article-title":"Retinal thickness in diabetic retinopathy: a study using optical coherence tomography (OCT)","volume":"22","author":"Goebel","year":"2002","journal-title":"Retina"},{"issue":"12","key":"10.1016\/j.survophthal.2025.04.004_bib46","doi-asserted-by":"crossref","first-page":"3799","DOI":"10.1007\/s00417-022-05697-4","article-title":"Correlation between change in central subfield thickness and change in visual acuity in macular edema due to retinal vein occlusion: post hoc analysis of COPERNICUS, GALILEO, and VIBRANT","volume":"260","author":"Gu","year":"2022","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"issue":"3","key":"10.1016\/j.survophthal.2025.04.004_bib47","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1159\/000514992","article-title":"Evaluation of macular changes in the long term after pars plana vitrectomy with internal limiting membrane peeling for diabetic macular edema","volume":"244","author":"Gunay","year":"2021","journal-title":"Ophthalmologica"},{"issue":"3","key":"10.1016\/j.survophthal.2025.04.004_bib48","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1177\/1120672119833267","article-title":"Correlation analysis of fundus autofluorescence, spectral domain optical coherence tomography, and visual function in patients with diabetic macular oedema treated with intravitreal ziv-aflibercept","volume":"29","author":"Hernandez-Da Mota","year":"2019","journal-title":"Eur J Ophthalmol"},{"issue":"4","key":"10.1016\/j.survophthal.2025.04.004_bib49","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1001\/jamaophthalmol.2018.0179","article-title":"Aqueous humor cytokine levels and anatomic response to intravitreal ranibizumab in diabetic macular edema","volume":"136","author":"Hillier","year":"2018","journal-title":"JAMA Ophthalmol"},{"key":"10.1016\/j.survophthal.2025.04.004_bib50","article-title":"Insights into cataract surgery outcomes in age-related macular degeneration: perspectives across severity grades under clinical routine conditions","author":"H\u00f6ssl","year":"2024","journal-title":"Ophthalmol Retin"},{"key":"10.1016\/j.survophthal.2025.04.004_bib51","unstructured":"IQWiG. Validity of surrogate endpoints in oncology. Executive Summaries [Internet]; 2011. \u3008https:\/\/www.iqwig.de\/en\/projects\/a10-05.html\u3009. [Accessed October 2024]."},{"issue":"7","key":"10.1016\/j.survophthal.2025.04.004_bib52","doi-asserted-by":"crossref","first-page":"1402","DOI":"10.1016\/j.ophtha.2015.02.006","article-title":"The REVEAL study: ranibizumab monotherapy or combined with laser versus laser monotherapy in Asian patients with diabetic macular edema","volume":"122","author":"Ishibashi","year":"2015","journal-title":"Ophthalmology"},{"issue":"5","key":"10.1016\/j.survophthal.2025.04.004_bib53","doi-asserted-by":"crossref","DOI":"10.1016\/j.disamonth.2021.101138","article-title":"Diabetic macular edema","volume":"67","author":"Ixcamey","year":"2021","journal-title":"Dis Mon"},{"key":"10.1016\/j.survophthal.2025.04.004_bib55","unstructured":"JBI. Critical appraisal tools; 2020. Available at: \u3008https:\/\/jbi.global\/critical-appraisal-tools\u3009 [Accessed April 2024]."},{"key":"10.1016\/j.survophthal.2025.04.004_bib56","doi-asserted-by":"crossref","first-page":"48","DOI":"10.2174\/1874364101307010048","article-title":"NAVILAS laser system focal laser treatment for diabetic macular edema \u2013 one year results of a case series","volume":"7","author":"Jung","year":"2013","journal-title":"Open Ophthalmol J"},{"issue":"8","key":"10.1016\/j.survophthal.2025.04.004_bib57","doi-asserted-by":"crossref","first-page":"e1054","DOI":"10.1111\/aos.14173","article-title":"Atrophy of the central neuroretina in patients treated for diabetic macular edema","volume":"97","author":"Karst","year":"2019","journal-title":"Acta Ophthalmol"},{"key":"10.1016\/j.survophthal.2025.04.004_bib58","doi-asserted-by":"crossref","DOI":"10.1155\/2018\/3978514","article-title":"Evaluation of navigated laser photocoagulation (Navilas 577+) for the treatment of refractory diabetic macular edema","volume":"2018","author":"Kato","year":"2018","journal-title":"J Ophthalmol"},{"key":"10.1016\/j.survophthal.2025.04.004_bib59","doi-asserted-by":"crossref","first-page":"1307","DOI":"10.2147\/OPTH.S34631","article-title":"Factors associated with visual recovery after sub-Tenon injection of triamcinolone acetonide in diabetic macular edema","volume":"6","author":"Kawashima","year":"2012","journal-title":"Clin Ophthalmol"},{"key":"10.1016\/j.survophthal.2025.04.004_bib60","doi-asserted-by":"crossref","first-page":"533","DOI":"10.2147\/OPTH.S237586","article-title":"Two year visual acuity and structural outcomes in patients with diabetic macular oedema treated with intravitreal aflibercept \u2013 a retrospective cohort study","volume":"14","author":"Kern","year":"2020","journal-title":"Clin Ophthal"},{"key":"10.1016\/j.survophthal.2025.04.004_bib61","doi-asserted-by":"crossref","DOI":"10.1155\/2021\/8117650","article-title":"Ellipsoid zone integrity and visual acuity changes during diabetic macular edema therapy: a longitudinal study","volume":"2021","author":"Kessler","year":"2021","journal-title":"J Diabetes Res"},{"issue":"7","key":"10.1016\/j.survophthal.2025.04.004_bib62","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1136\/bjo.2008.152553","article-title":"Optical coherence tomographic patterns in diabetic macular oedema: prediction of visual outcome after focal laser photocoagulation","volume":"93","author":"Kim","year":"2009","journal-title":"Br J Ophthalmol"},{"issue":"10","key":"10.1016\/j.survophthal.2025.04.004_bib63","doi-asserted-by":"crossref","first-page":"2635","DOI":"10.1007\/s10792-020-01444-y","article-title":"The effects of epiretinal membranes on the treatment outcomes of intravitreal aflibercept injection in diabetic macular edema: a real-life study","volume":"40","author":"Kocak Altintas","year":"2020","journal-title":"Int Ophthalmol"},{"issue":"2","key":"10.1016\/j.survophthal.2025.04.004_bib64","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1159\/000528426","article-title":"Optical coherence tomography angiography in diabetic macular edema treated with intravitreal aflibercept: a 48-week observational study (the DOCTA study)","volume":"246","author":"Korobelnik","year":"2023","journal-title":"Ophthalmologica"},{"issue":"2","key":"10.1016\/j.survophthal.2025.04.004_bib65","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1159\/000528426","article-title":"Optical coherence tomography angiography in diabetic macular edema treated with intravitreal aflibercept: a 48-week observational study (the DOCTA study)","volume":"246","author":"Korobelnik","year":"2023","journal-title":"Ophthalmologica"},{"issue":"6","key":"10.1016\/j.survophthal.2025.04.004_bib66","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1038\/eye.2013.17","article-title":"Effect of a single intravitreal bevacizumab injection on different optical coherence tomographic patterns of diabetic macular oedema","volume":"27","author":"Koytak","year":"2013","journal-title":"Eye"},{"issue":"3","key":"10.1016\/j.survophthal.2025.04.004_bib67","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1007\/s00417-006-0456-6","article-title":"Comparative evaluation of vitrectomy and dye-enhanced ILM peel with grid laser in diffuse diabetic macular edema","volume":"245","author":"Kumar","year":"2007","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"issue":"6","key":"10.1016\/j.survophthal.2025.04.004_bib68","doi-asserted-by":"crossref","first-page":"990","DOI":"10.1177\/112067210901900615","article-title":"Optical coherence tomography of macular thickness after biaxial vs coaxial microincision clear corneal cataract surgery","volume":"19","author":"Kurz","year":"2009","journal-title":"Eur J Ophthalmol"},{"issue":"12","key":"10.1016\/j.survophthal.2025.04.004_bib69","first-page":"4048","article-title":"Photoreceptor function in eyes with macular edema","volume":"41","author":"Lardenoye","year":"2000","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"9","key":"10.1016\/j.survophthal.2025.04.004_bib70","article-title":"Effectiveness of subthreshold laser therapy for non-center-involving diabetic macular edema","volume":"60","author":"Lim","year":"2019","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"1","key":"10.1016\/j.survophthal.2025.04.004_bib71","first-page":"25","article-title":"Retinal thickness after focal photocoagulation for diabetic macular edema with and without temporal perifoveal thickening","volume":"67","author":"Lima Gomez","year":"2015","journal-title":"Rev Invest Clin"},{"issue":"9","key":"10.1016\/j.survophthal.2025.04.004_bib72","doi-asserted-by":"crossref","first-page":"1378","DOI":"10.1080\/02713683.2021.1878540","article-title":"Dril influences short-term visual outcome after intravitreal corticosteroid injection for refractory diabetic macular edema","volume":"46","author":"Luis","year":"2021","journal-title":"Curr Eye Res"},{"issue":"3","key":"10.1016\/j.survophthal.2025.04.004_bib73","doi-asserted-by":"crossref","first-page":"1201","DOI":"10.1177\/1120672120925034","article-title":"Intravitreal aflibercept for diabetic macular oedema in real-world: 36-month visual acuity and anatomical outcomes","volume":"31","author":"Lukic","year":"2021","journal-title":"Eur J Ophthalmol"},{"issue":"3","key":"10.1016\/j.survophthal.2025.04.004_bib74","doi-asserted-by":"crossref","first-page":"1171","DOI":"10.1177\/1120672120927275","article-title":"One-year real-life results on effect of intravitreal aflibercept in patients with diabetic macular oedema switched from ranibizumab","volume":"31","author":"Lukic","year":"2021","journal-title":"Eur J Ophthalmol"},{"issue":"3","key":"10.1016\/j.survophthal.2025.04.004_bib75","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1177\/1120672119833270","article-title":"Intravitreal aflibercept for diabetic macular oedema: Moorfields' real-world 12-month visual acuity and anatomical outcomes","volume":"30","author":"Lukic","year":"2020","journal-title":"Eur J Ophthalmol"},{"issue":"1","key":"10.1016\/j.survophthal.2025.04.004_bib76","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/j.ajo.2010.01.039","article-title":"The association between percent disruption of the photoreceptor inner segment\u2013outer segment junction and visual acuity in diabetic macular edema","volume":"150","author":"Maheshwary","year":"2010","journal-title":"Am J Ophthalmol"},{"issue":"2","key":"10.1016\/j.survophthal.2025.04.004_bib77","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1016\/j.ajo.2008.08.024","article-title":"Combined laser and intravitreal triamcinolone for proliferative diabetic retinopathy and macular edema: one-year results of a randomized clinical trial","volume":"147","author":"Maia","year":"2009","journal-title":"Am J Ophthalmol"},{"issue":"1","key":"10.1016\/j.survophthal.2025.04.004_bib78","article-title":"Long-term outcomes and OCT-biomarkers after fluocinolone acetonide intravitreal implant in diabetic macular edema: a real-world study","volume":"244","author":"Maleita","year":"2021","journal-title":"EURETINA"},{"key":"10.1016\/j.survophthal.2025.04.004_bib79","doi-asserted-by":"crossref","DOI":"10.1155\/2021\/6612126","article-title":"A real-world single-centre study of patients with diabetic macular oedema who wore a home-use sleep mask (noctura 400) for one year","volume":"2021","author":"Meyer-Bothling","year":"2021","journal-title":"J Ophthalmol"},{"issue":"2","key":"10.1016\/j.survophthal.2025.04.004_bib80","doi-asserted-by":"crossref","first-page":"105","DOI":"10.12816\/0014421","article-title":"Influence of intravitreal bevacizumab therapy on the patterns of diabetic maculopathy on optical coherence tomography","volume":"37","author":"Mian","year":"2015","journal-title":"BMB"},{"issue":"10","key":"10.1016\/j.survophthal.2025.04.004_bib81","first-page":"2127","article-title":"Methodological quality of case series studies: an introduction to the JBI critical appraisal tool","volume":"18","author":"Munn","year":"2020","journal-title":"JBI Evid Synth"},{"issue":"2","key":"10.1016\/j.survophthal.2025.04.004_bib82","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1016\/j.ajo.2010.08.022","article-title":"Association of pathomorphology, photoreceptor status, and retinal thickness with visual acuity in diabetic retinopathy","volume":"151","author":"Murakami","year":"2011","journal-title":"Am J Ophthalmol"},{"issue":"3","key":"10.1016\/j.survophthal.2025.04.004_bib83","first-page":"133","article-title":"Diabetic macular edema","volume":"59","author":"Musat","year":"2015","journal-title":"Rom J Opthalmol"},{"issue":"6","key":"10.1016\/j.survophthal.2025.04.004_bib84","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1016\/j.ajo.2006.06.068","article-title":"Vascular endothelial growth factor is a critical stimulus for diabetic macular edema","volume":"142","author":"Nguyen","year":"2006","journal-title":"Am J Ophthalmol"},{"issue":"3","key":"10.1016\/j.survophthal.2025.04.004_bib85","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1007\/s10384-019-00662-x","article-title":"Indocyanine green angiography-guided focal navigated laser photocoagulation for diabetic macular edema","volume":"63","author":"Nozaki","year":"2019","journal-title":"JpnJ Ophthalmol"},{"issue":"12","key":"10.1016\/j.survophthal.2025.04.004_bib86","doi-asserted-by":"crossref","first-page":"1581","DOI":"10.1136\/bjo.2008.144550","article-title":"Interventions for diabetic macular oedema: a systematic review of the literature","volume":"92","author":"O\u2019Doherty","year":"2008","journal-title":"Br J Ophthalmol"},{"issue":"6","key":"10.1016\/j.survophthal.2025.04.004_bib87","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1136\/bjo.2007.131771","article-title":"Intravitreal triamcinolone versus laser photocoagulation for persistent diabetic macular oedema","volume":"92","author":"Ockrim","year":"2008","journal-title":"Br J Ophthalmol"},{"issue":"1","key":"10.1016\/j.survophthal.2025.04.004_bib88","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/j.ajo.2009.08.010","article-title":"Subthreshold micropulse diode laser photocoagulation for diabetic macular edema in Japanese patients","volume":"149","author":"Ohkoshi","year":"2010","journal-title":"Am J Ophthalmol"},{"issue":"1","key":"10.1016\/j.survophthal.2025.04.004_bib89","doi-asserted-by":"crossref","first-page":"40","DOI":"10.3390\/jpm3010040","article-title":"Personalized medicine in ophthalmology: from pharmacogenetic biomarkers to therapeutic and dosage optimization","volume":"3","author":"Ong","year":"2013","journal-title":"J Pers Med"},{"key":"10.1016\/j.survophthal.2025.04.004_bib90","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijsu.2021.105906","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"88","author":"Page","year":"2021","journal-title":"Int J Surg"},{"issue":"6","key":"10.1016\/j.survophthal.2025.04.004_bib91","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1038\/sj.eye.6701945","article-title":"Pars plana vitrectomy for diabetic macular oedema: OCT and functional correlations","volume":"20","author":"Patel","year":"2006","journal-title":"Eye"},{"issue":"1","key":"10.1016\/j.survophthal.2025.04.004_bib92","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1097\/00006982-200601000-00002","article-title":"Pars plana vitrectomy with and without peeling of the inner limiting membrane for diabetic macular edema","volume":"26","author":"Patel","year":"2006","journal-title":"Retina"},{"key":"10.1016\/j.survophthal.2025.04.004_bib93","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.ajo.2016.09.002","article-title":"Real-world outcomes of ranibizumab treatment for diabetic macular edema in a United Kingdom national health service setting","volume":"172","author":"Patrao","year":"2016","journal-title":"Am J Ophthalmol"},{"issue":"10","key":"10.1016\/j.survophthal.2025.04.004_bib94","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0223793","article-title":"Evaluation of ranibizumab and aflibercept for the treatment of diabetic macular edema in daily clinical practice","volume":"14","author":"Plaza-Ramos","year":"2019","journal-title":"PLoS One"},{"key":"10.1016\/j.survophthal.2025.04.004_bib95","unstructured":"PRISMA. PRISMA Checklist; 2022. Available at: \u3008http:\/\/www.prisma-statement.org\/PRISMAStatement\/Checklist\u3009 [Accessed October 2024]."},{"issue":"4","key":"10.1016\/j.survophthal.2025.04.004_bib96","doi-asserted-by":"crossref","first-page":"CR241","DOI":"10.12659\/MSM.882624","article-title":"Triple therapy: phaco-vitrectomy with ILM peeling, retinal endophotocoagulation, and intraoperative use of bevacizumab for diffuse diabetic macular edema","volume":"18","author":"Robaszkiewicz","year":"2012","journal-title":"Med Sci Monit"},{"issue":"10","key":"10.1016\/j.survophthal.2025.04.004_bib97","doi-asserted-by":"crossref","first-page":"1066","DOI":"10.1016\/j.ophtha.2023.05.023","article-title":"SCORE2 Report 24: nonlinear relationship of retinal thickness and visual acuity in central retinal and hemiretinal vein occlusion","volume":"130","author":"Scott","year":"2023","journal-title":"Ophthalmology"},{"issue":"4","key":"10.1016\/j.survophthal.2025.04.004_bib98","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1016\/j.jcjo.2017.10.008","article-title":"Effect of glycosylated hemoglobin on response to ranibizumab therapy in diabetic macular edema: real-world outcomes in 312 patients","volume":"53","author":"Shalchi","year":"2018","journal-title":"Can J Ophthalmol"},{"issue":"3","key":"10.1016\/j.survophthal.2025.04.004_bib99","first-page":"391","article-title":"Correlation between visual function and photoreceptor integrity in diabetic macular edema: spectral-domain optical coherence tomography","volume":"41","author":"Shen","year":"2016","journal-title":"Curr Eye Res"},{"issue":"7","key":"10.1016\/j.survophthal.2025.04.004_bib100","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1111\/j.1442-9071.2011.02504.x","article-title":"Intravitreal triamcinolone acetonide versus combined intravitreal bevacizumab and dexamethasone in diffuse diabetic macular oedema","volume":"39","author":"Sheth","year":"2011","journal-title":"Clin Exp Ophthalmol"},{"issue":"7","key":"10.1016\/j.survophthal.2025.04.004_bib101","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1111\/j.1442-9071.2011.02504.x","article-title":"Intravitreal triamcinolone acetonide versus combined intravitreal bevacizumab and dexamethasone in diffuse diabetic macular oedema","volume":"39","author":"Sheth","year":"2011","journal-title":"Clin Exp Ophthalmol"},{"issue":"3","key":"10.1016\/j.survophthal.2025.04.004_bib102","doi-asserted-by":"crossref","first-page":"2353","DOI":"10.1167\/iovs.12-11103","article-title":"The effects of macular ischemia on visual acuity in diabetic retinopathy","volume":"54","author":"Sim","year":"2013","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"3","key":"10.1016\/j.survophthal.2025.04.004_bib103","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1111\/j.1600-0420.2007.01048.x","article-title":"The predictive value of optical coherence tomography after grid laser photocoagulation for diffuse diabetic macular oedema","volume":"86","author":"Soliman","year":"2008","journal-title":"Acta Ophthalmol"},{"issue":"4","key":"10.1016\/j.survophthal.2025.04.004_bib104","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1111\/j.1600-0420.2007.01057.x","article-title":"Optical coherence tomography and vessel diameter changes after intravitreal bevacizumab in diabetic macular oedema","volume":"86","author":"Soliman","year":"2008","journal-title":"Acta Ophthalmol"},{"key":"10.1016\/j.survophthal.2025.04.004_bib105","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/j.ajo.2019.11.014","article-title":"Effect of intravitreal ranibizumab on intraretinal hard exudates in eyes with diabetic macular edema","volume":"211","author":"Srinivas","year":"2020","journal-title":"Am J Ophthalmol"},{"issue":"2","key":"10.1016\/j.survophthal.2025.04.004_bib106","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1111\/opo.12263","article-title":"Retinal thickness profile of individuals with diabetes","volume":"36","author":"Srinivasan","year":"2016","journal-title":"Ophthalmic Physiol Opt"},{"key":"10.1016\/j.survophthal.2025.04.004_bib107","doi-asserted-by":"crossref","DOI":"10.1155\/2020\/6655021","article-title":"Optical coherence tomography (angiography) biomarkers in the assessment and monitoring of diabetic macular edema","volume":"2020","author":"Suciu","year":"2020","journal-title":"J Diabetes Res"},{"key":"10.1016\/j.survophthal.2025.04.004_bib108","doi-asserted-by":"crossref","DOI":"10.1016\/j.diabres.2021.109119","article-title":"IDF diabetes atlas: global, regional and country-level diabetes prevalence estimates for 2021 and projections for 2045","volume":"183","author":"Sun","year":"2022","journal-title":"Diabetes Res Clin Pract"},{"key":"10.1016\/j.survophthal.2025.04.004_bib109","doi-asserted-by":"crossref","first-page":"2099","DOI":"10.2147\/OPTH.S150385","article-title":"Six-month postoperative outcomes of intraoperative OCT-guided surgical cystotomy for refractory cystoid macular edema in diabetic eyes","volume":"11","author":"Tachi","year":"2017","journal-title":"Clin Ophthalmol"},{"key":"10.1016\/j.survophthal.2025.04.004_bib110","doi-asserted-by":"crossref","first-page":"5606343","DOI":"10.1155\/2022\/5606343","article-title":"Efficacy and safety of intravitreal injection of triamcinolone acetonide and conbercept for intraocular lens after cataract surgery","volume":"2022","author":"Tang","year":"2022","journal-title":"Evid-Based Complement Altern Med: eCAM"},{"issue":"9","key":"10.1016\/j.survophthal.2025.04.004_bib111","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1038\/s41574-022-00690-7","article-title":"The burden and risks of emerging complications of diabetes mellitus","volume":"18","author":"Tomic","year":"2022","journal-title":"Nat Rev Endocrinol"},{"key":"10.1016\/j.survophthal.2025.04.004_bib112","doi-asserted-by":"crossref","first-page":"603","DOI":"10.2147\/OPTH.S352152","article-title":"Two-year outcome of intravitreal aflibercept injection in vitrectomized eyes with diabetic macular edema","volume":"16","author":"Tran","year":"2022","journal-title":"Clin Ophthalmol"},{"issue":"1","key":"10.1016\/j.survophthal.2025.04.004_bib113","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1186\/s40942-022-00430-z","article-title":"Short-term outcomes in patients with center-involving diabetic macular edema after a single dose of intravitreal bevacizumab","volume":"8","author":"Turski","year":"2022","journal-title":"Int J Retin Vitr"},{"issue":"2","key":"10.1016\/j.survophthal.2025.04.004_bib114","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1159\/000503036","article-title":"The outcomes of switching from short- to long-term intravitreal corticosteroid implant therapy in patients with diabetic macular edema","volume":"63","author":"Vaz-Pereira","year":"2020","journal-title":"Ophthalmic Res"},{"issue":"1","key":"10.1016\/j.survophthal.2025.04.004_bib115","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1186\/s40942-023-00473-w","article-title":"OCT biomarkers as predictors of visual improvement in diabetic macular edema eyes receiving dexamethasone implants","volume":"9","author":"Visioli","year":"2023","journal-title":"Int J Retin Vitr"},{"issue":"7","key":"10.1016\/j.survophthal.2025.04.004_bib116","doi-asserted-by":"crossref","first-page":"1298","DOI":"10.1097\/IAE.0000000000000912","article-title":"Hyperreflective retinal spots and visual function after anti-vascular endothelial growth factor treatment in center-involving diabetic macular edema","volume":"36","author":"Vujosevic","year":"2016","journal-title":"Retina"},{"issue":"1","key":"10.1016\/j.survophthal.2025.04.004_bib117","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1177\/24741264221138722","article-title":"Relationship between macular thickness and visual acuity in the treatment of diabetic macular edema with anti-VEGF therapy: systematic review","volume":"7","author":"Wang","year":"2023","journal-title":"J Vitreoretin Dis"},{"issue":"6","key":"10.1016\/j.survophthal.2025.04.004_bib118","doi-asserted-by":"crossref","first-page":"1351","DOI":"10.1016\/j.ophtha.2016.02.022","article-title":"Aflibercept, bevacizumab, or ranibizumab for diabetic macular edema: two-year results from a comparative effectiveness randomized clinical trial","volume":"123","author":"Wells","year":"2016","journal-title":"Ophthalmology"},{"issue":"1","key":"10.1016\/j.survophthal.2025.04.004_bib119","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1089\/jop.2011.0070","article-title":"Optical coherence tomographic patterns in diabetic macula edema can predict the effects of intravitreal bevacizumab injection as primary treatment","volume":"28","author":"Wu","year":"2012","journal-title":"J Ocul Pharmacol Ther"},{"issue":"6","key":"10.1016\/j.survophthal.2025.04.004_bib120","doi-asserted-by":"crossref","first-page":"1254","DOI":"10.1016\/j.ophtha.2012.12.003","article-title":"Association of retinal sensitivity to integrity of photoreceptor inner\/outer segment junction in patients with diabetic macular edema","volume":"120","author":"Yohannan","year":"2013","journal-title":"Ophthalmology"},{"issue":"4","key":"10.1016\/j.survophthal.2025.04.004_bib121","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1007\/s10792-013-9884-6","article-title":"Reduced effect of anti-vascular endothelial growth factor agents on diabetics with vitreomacular interface abnormalities","volume":"34","author":"Yoon","year":"2014","journal-title":"Int Ophthalmol"},{"issue":"5","key":"10.1016\/j.survophthal.2025.04.004_bib122","doi-asserted-by":"crossref","first-page":"398","DOI":"10.3341\/kjo.2022.0086","article-title":"Clinical characteristics and long-term outcomes in diabetic macular edema patients: with or without additional injection following ranibizumab loading","volume":"36","author":"Yoon","year":"2022","journal-title":"Korean J Ophthalmol"},{"issue":"21","key":"10.1016\/j.survophthal.2025.04.004_bib123","doi-asserted-by":"crossref","first-page":"3362","DOI":"10.3390\/cells11213362","article-title":"Diabetic macular edema: current understanding, molecular mechanisms and therapeutic implications","volume":"11","author":"Zhang","year":"2022","journal-title":"Cells"}],"container-title":["Survey of Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0039625725000694?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0039625725000694?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,22]],"date-time":"2025-09-22T11:58:01Z","timestamp":1758542281000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0039625725000694"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11]]},"references-count":122,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2025,11]]}},"alternative-id":["S0039625725000694"],"URL":"https:\/\/doi.org\/10.1016\/j.survophthal.2025.04.004","relation":{},"ISSN":["0039-6257"],"issn-type":[{"value":"0039-6257","type":"print"}],"subject":[],"published":{"date-parts":[[2025,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Anatomic biomarkers as potential endpoints in diabetic macular edema: A systematic literature review with identification of macular volume as a key surrogate for visual acuity","name":"articletitle","label":"Article Title"},{"value":"Survey of Ophthalmology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.survophthal.2025.04.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}